A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR (RM) in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET)

Trial Profile

A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR (RM) in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Octreotide
  • Indications Gastrointestinal cancer; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms EVERLAR
  • Most Recent Events

    • 29 May 2017 Planned End Date changed from 1 Apr 2018 to 7 Jun 2017.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 03 Nov 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2018 as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top